The Human Variable 

Infection-associated chronic conditions (IACCs) describe a single clinical terrain that appears under many labels—Long COVID, ME/CFS, POTS, MCAS, hEDS overlap, and post-infectious states following EBV, H1N1, Lyme, and Ebola. Triggers differ; downstream biology converges. Across cohorts, patients show immune dysregulation, autonomic instability, mitochondrial hypometabolism, mast-cell mediator sensitivity, connective-tissue fragility, and chronic neuroinflammation.

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

This white paper argues that MCS and MCAS are vantage points on a shared hypersensitivity terrain, proposing a new classification, Multi-Chemical and Environmental Hypersensitivity Disorders (MCEHD), that unites them, honors patient ingenuity, and formalizes my frameworks.

The CYNAERA ME/CFS Individualized Regimen Engine™ is an educational modeling framework that simulates phased strategies for ME/CFS care. Built on CYNAERA’s ecosystem of validated modules — including Treatment Archetypes, Phenotyping Framework, Pathophysiology Drivers, and the Path of Remission Model — the Regimen Engine demonstrates how individualized patient care can be systematically structured.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is profoundly sensitive to environmental stressors. Pollutants such as polycyclic aromatic hydrocarbons (PAHs), particulate matter (PM₂.₅, PM₁₀), nitrogen dioxide (NO₂), ground-level ozone (O₃), sulfur dioxide (SO₂), and volatile organic compounds (VOCs), combined with weather triggers like heat, cold, barometric pressure swings, mold, humidity, and pollen, drive flares that push patients into cycles of severe disabi

Clinician Guide For MECFS Therapeutics: Built from CYNAERA Diagnostic Fingerprints™ + IACCI Terrain Logic + XR/CR Pharmacology Doctrine